Studies inflammation in vitiligo and other inflammatory skin diseases using samples
Collects blood and skin samples from adults with vitiligo, psoriasis, atopic dermatitis or alopecia areata.
Plain-language title generated from the registry record
Registry title: Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
Key facts
- Where
- Bordeaux, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT03976622, who can take part
Where in France
- Service de Dermatologie - Hôpital Saint-AndréBordeaux, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Bordeaux
- Trial code
- NCT03976622
- Record updated
- 18 June 2026
- Original description
It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disordersRead full original descriptionShow less
Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata
It is a study of translational research with mechanistically objectives and including biological samples of patients with chronic inflammatory disorders
Inclusion: Patients aged 18 to 75 years; Patients with non-segmental vitiligo; Patients with plaque psoriasis; Patients with atopic dermatitis; Patients with alopecia areata sclerosis; written consent, free, informed and signed by the patient and the investigator (before any examination required by the study); Subject affiliated or beneficiary of a social security system.
Exclusion: Patients under local treatment (topical corticosteroid-Calcineurin inhibitor) for less than two weeks; Patients on therapy, systemic treatments: acitretin, methotrexate, cyclosporine, Apremilast, infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, dupilumab) for less than 4 weeks; Patients with segmental vitiligo; Pregnant or breastfeeding women; Patient (e) under guardianship; Patient (e) Non-affiliated (e) a social protection.